Scilex Holding SCLX
NASDAQ SCLX
$5.20 -0.17 (-3.17%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scilex Holding (SCLX) Non Operating Interest Expenses (2021 - 2026)

Scilex Holding (SCLX) posted Non Operating Interest Expenses of $6.1 million for Q2 2026, up 61.52% on a QoQ basis from $3.8 million in Q1 2026, and up 127.59% year-over-year from $2.7 million in Q2 2025.

Analysis

Scilex Holding (SCLX) Non Operating Interest Expenses (2021 - 2026) Analysis & Trends

Scilex Holding has reported Non Operating Interest Expenses for 6 years, with the latest figure at $6.1 million in Q2 2026.

  • On a quarterly basis, Non Operating Interest Expenses rose 127.59% year-over-year to $6.1 million in Q2 2026; TTM through Jun 2026 was $16.2 million, a 168.58% increase from a year earlier, with the FY2025 full-year figure at $11.5 million, up 483.75% from the prior year.
  • Non Operating Interest Expenses was $6.1 million for Q2 2026 at Scilex Holding, up from $3.8 million in the prior quarter.
  • The five-year high for Non Operating Interest Expenses was $6.1 million in Q2 2026, with the low at $7466.0 in Q1 2022.
  • Average Non Operating Interest Expenses over 5 years is $2.0 million, with a median of $1.4 million recorded in 2022.
  • The sharpest annual moves came in 2023 and 2024: Non Operating Interest Expenses surged 70513.45% in 2023, then tumbled 89.93% in 2024.
  • Over 5 years, Non Operating Interest Expenses stood at $1.0 million in 2022, then tumbled by 45.34% to $551000.0 in 2023, then plunged by 48.28% to $285000.0 in 2024, then jumped by 1127.37% to $3.5 million in 2025, then surged by 74.5% to $6.1 million in 2026.
  • The last three Non Operating Interest Expenses figures came in at $6.1 million (Q2 2026), $3.8 million (Q1 2026), and $3.5 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Johnson & Johnson 643.26 Bn 622.50 Bn 17.26 Bn 281.00 Mn
2 AbbVie 443.31 Bn 436.74 Bn 12.70 Bn -
3 Merck 364.74 Bn 357.60 Bn 12.21 Bn -
4 Novartis Ag 266.46 Bn 258.77 Bn 11.24 Bn -462.00 Mn
5 Pfizer 158.57 Bn 146.88 Bn 10.94 Bn -
6 Sanofi 52.33 Bn 44.95 Bn 10.79 Bn -333.60 Mn
7 Revolution Medicines 43.79 Bn 43.79 Bn - 23.78 Mn
8 Incyte 25.23 Bn 20.69 Bn 1.57 Bn 582,000.00
9 United Therapeutics 21.67 Bn 19.01 Bn 683.80 Mn 2.90 Mn
10 Scilex Holding 35.91 Mn -76.88 Mn 3.97 Mn 6.10 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 6.10 Mn
Mar 31, 2026 3.78 Mn
Dec 31, 2025 3.50 Mn
Sep 30, 2025 2.80 Mn
Jun 30, 2025 2.68 Mn
Mar 31, 2025 2.48 Mn
Dec 31, 2024 285,000.00
Sep 30, 2024 576,000.00
Jun 30, 2024 571,000.00
Mar 31, 2024 531,000.00
Dec 31, 2023 551,000.00
Sep 30, 2023 513,000.00
Jun 30, 2023 3.84 Mn
Mar 31, 2023 5.27 Mn
Dec 31, 2022 1.01 Mn
Sep 30, 2022 1.86 Mn
Jun 30, 2022 8,280.00
Mar 31, 2022 7,466.00
Dec 31, 2021 50,000.00